Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture
International Journal of Molecular Sciences · 25.01.2023 · 24 (3) · 2398
DOI: 10.3390/ijms24032398 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.01.2023. Verfasst von Silvia Martina Ferrari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anaplastic thyroid cancer (ATC) is a rare and rapidly fatal human cancer. Its usual treatment includes the combination of surgery, external hyperfractionated radiation therapy, and chemotherapy. These treatments permit achieving about 6–10 months of median survival. For this reason, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c-Kit. Until now, the effect of pazopanib in primary human ATC cells (pATC) has not been reported in the literature. The aim of our study was to evaluate in vitro the antineoplastic effect of pazopanib in pATC. Surgical thyroidal tissues were collected from five patients with ATC, from thyroid biopsy at the moment of first surgical operation. An inhibition of proliferation, migration, and invasion, and an increase in apoptosis were demonstrated upon treating pATC cells with pazopanib (p < 0.05). Moreover, pazopanib was able to significantly decrease the VEGF expression in pATC cells (p < 0.05). To conclude, in this study, we demonstrate the antineoplastic activity of the antiangiogenic inhibitor, pazopanib, in human pATC in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
- Department of Surgery, Medical and Molecular Pathology and of Critical Area, University of Pisa, 56126 Pisa, Italy.
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
- Department of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.
- Department of Surgical Sciences, Sapienza University of Rome, 00161 Rome, Italy.
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00185 Latina, Italy.
ORCID-Profile: Armando Patrizio, Enke Baldini, Marco Centanni, Concettina La Motta, Alessandro Antonelli
Zitieren
APA
Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Mazzi, V., Patrizio, A., Piaggi, S., Baldini, E., Centanni, M., La Motta, C., Antonelli, A., & Fallahi, P. (2023). Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture. International Journal of Molecular Sciences, 24(3), 2398. https://doi.org/10.3390/ijms24032398
Vancouver
Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, Patrizio A, et al. Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture. International Journal of Molecular Sciences. 2023;24(3):2398. doi:10.3390/ijms24032398
BibTeX
@article{Ferrari2023,
author = {Ferrari, Silvia Martina and Elia, Giusy and Ragusa, Francesca and Paparo, Sabrina Rosaria and Mazzi, Valeria and Patrizio, Armando and Piaggi, Simona and Baldini, Enke and Centanni, Marco and La Motta, Concettina and Antonelli, Alessandro and Fallahi, Poupak},
title = {Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {3},
pages = {2398},
doi = {10.3390/ijms24032398}
}
EUVIMED